BiomX to Present at Upcoming April Investor Events

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that Jonathan Solomon, Chief Executive Officer of BiomX, will be presenting at two upcoming virtual investor events in April.

Presentation Details:

Event: Jefferies Microbiome-Based Therapeutics Summit
Date: Thursday, April 22, 2021
Time: On-demand beginning at 8:00 AM EDT

Event: Ladenburg Thalmann R&D Showcase
Date: Thursday, April 29, 2021
Time: 1:00 PM EDT
Format: Mr. Solomon will be joined by Key Opinion Leader, Dr. Leon Kircik, to discuss the acne landscape and BiomX’s lead product candidate, BX001.

Live webcasts from the Jefferies Microbiome-Based Therapeutics Summit and Ladenburg Thalmann R&D Showcase will be accessible through the Investors section of the Company’s website at ir.biomx.com/news-events/ir-calendar. Following the events, the webcasts will be archived on the BiomX website.

About BiomX

BiomX is a clinical-stage microbiome company developing both natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of skin, as well as target bacteria in the treatment of chronic diseases, such as inflammatory bowel disease, primary sclerosing cholangitis, cystic fibrosis, atopic dermatitis and colorectal cancer. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.

Additional information is available at www.biomx.com, the content of which does not form a part of this press release.